Rani Therapeutics

RANIPhase 1

Rani Therapeutics has developed a disruptive technology platform, the RaniPill™, designed to enable the oral delivery of biologic drugs that currently require injection. The company has demonstrated high reliability, safety, and bioavailability comparable to subcutaneous injections in multiple preclinical and clinical studies. Its mission is to improve patient compliance and quality of life for millions with chronic conditions by eliminating the need for needles. Rani is advancing a pipeline of oral biologics, with lead candidates showing promising Phase 1 results in osteoporosis and inflammatory diseases.

Market Cap

$110.2M

-21.5% period

Pipeline

drug candidates

Patents

—

Publications

—

RANI · Stock Price

USD 1.130.31 (-21.53%)

Historical price data

AI Company Overview

OsteoporosisInflammatory DiseasesAutoimmune DiseasesEndocrinology

Technology Platform

The RaniPill™ is an ingestible capsule that autonomously injects a solid-state formulation of biologic drugs (proteins, peptides, antibodies) into the intestinal wall for pain-free, oral systemic delivery.

Pipeline

3 drugs in pipeline

Drug	Indication	Stage
Forteo	Healthy Volunteers	Phase 1
PG-102	Obesity	Phase 1
Stelara	Healthy Volunteers	Phase 1

Funding History

Total raised:$259M

IPO$100MUndisclosedJul 29, 2021

Series D$69MUndisclosedJun 15, 2020

Series C$53MUndisclosedJun 15, 2017

Series B$27MUndisclosedJun 15, 2015

Opportunities

The primary opportunity is to convert the multi-hundred billion dollar injectable biologic market into an oral format, dramatically improving patient compliance for chronic diseases.

The platform's flexibility also allows for partnerships with large pharma to develop oral versions of their existing blockbuster drugs and new biologic entities.

Risk Factors

Key risks include the clinical and regulatory complexity of a novel device-drug combination product, challenges in scaling manufacturing of the mechanical capsule, and future competition in the oral biologics space.

As a pre-revenue company, it is also dependent on raising capital to fund expensive clinical trials.

Competitive Landscape

Rani competes with other oral delivery biotechs (e.g., Oramed, Entera Bio) using chemical enhancers and large pharma internal programs. Its main differentiation is the mechanical RaniPill device, which may enable delivery of larger molecules like antibodies, but adds device-related development and regulatory complexity.